The Liver Meeting® 2019 ePosters: Hepatitis B

  • 0454: SIMILAR RISK OF HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT DURING LONG-TERM ENTECAVIR (ETV) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) THERAPY IN CAUCASIAN CHRONIC HEPATITIS B (CHB) PATIENTS
    Authors: George Papatheodoridis, George Dalekos, Cihan Yurdaydin, Vana Sypsa, Florian van Bömmel, Maria Buti, Jose Luis Calleja, Ioannis Goulis, Spilios Manolakopoulos, Alessandro Loglio, Margarita Papatheodoridi, Nikolaos Gatselis, Onur Keskin, Rhea Veelken, Marta Lopez gomez, Bettina Hansen, Savvoula Savvidou, Anastasia Kourikou, Jiannis Vlachogi
    You must log in to access content.
  • 0457: HBsAg loss rates remain low during 3-year follow-up of HBeAg negative patients with chronic hepatitis B after nucleos(t)ide analogue withdrawal: results of the Toronto STOP Study
    Authors: Bahareh Moazen, Kin Seng Liem, Scott Fung, David Wong, Jiayun Chen, Colina Yim, Seham Noureldin, Jordan Feld, Bettina Hansen, Harry Janssen
    You must log in to access content.
  • 0459: TENOFOVIR VERSUS ENTECAVIR FOR HEPATOCELLULAR CARCINOMA PREVENTION IN AN INTERNATIONAL CONSORTIUM OF CHRONIC HEPATITIS B
    Authors: Yao-Chun Hsu, Grace Wong, Chien Hung Chen, Cheng-Yuan Peng, Ming-Lun Yeh, Ka-Shing Cheung, Hidenori Toyoda, Chung-Feng Huang, Huy Trinh, Qing Xie, Masaru Enomoto, Li Liu, Satoshi Yasuda, Yasuhito Tanaka, Ritsuzo Kozuka, Pei-Chien Tsai, Yen-Tsung Huang, Christopher Wong, Rui Huang, Tyng-Yuan Jang, Joseph Hoang, Dong Hyun Lee, Hwai-I Yang, J
    You must log in to access content.
  • 0461: SERUM HBCRAG PROFILES IN CHRONIC HEPATITIS B PATIENTS TREATED WITH FIRST-LINE ORAL ANTIVIRAL THERAPY
    Authors: Lung Yi Mak, Danny Ka Ho Wong, Wai-Kay Seto, James Fung, Ching Lung Lai, Man Fung Yuen
    You must log in to access content.
  • 0464: ON-THERAPY HBsAg KINETICS ARE ASSOCIATED WITH HBsAg KINETICS AFTER DISCONTINUATION OF NUCLEOS(T)IDE ANALOGUES (NA) IN NON-CIRRHOTIC HBEAG-NEGATIVE CHRONIC HEPATITIS B (CHBE-)
    Authors: George Papatheodoridis, Emilia Hadziyannis, Stephanos Hadziyannis
    You must log in to access content.
  • 0469: THE OPTIMAL DURATION OF CONSOLIDATION TREATMENT PRIOR TO CESSATION OF NUC THERAPY IN HBEAG-NEGATIVE PATIENTS
    Authors: Wen-Juei Jeng, Yi-Cheng Chen, I-Shyan Sheen, Rong-Nan Chien, Yun-Fan Liaw
    You must log in to access content.
  • 0470: HBsAg LEVELS AT THE END OF LONG-TERM THERAPY (EOT) WITH NUCLEOS(T)IDE ANALOGUES (NA) AFFECT THE ΟUTCOMES OF NON-CIRRHOTIC PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B (CHBE-)
    Authors: George Dalekos, Margarita Papatheodoridi, Emilia Hadziyannis, Afroditi Orfanidou, Kalliopi Zachou, Anastasia Kourikou, Anastasia Tzakou, Spilios Manolakopoulos, Stephanos Hadziyannis, George Papatheodoridis
    You must log in to access content.
  • 0471: DISCONTINUATION OF EFFECTIVE LONG-TERM NUCLEOS(T)IDE ANALOGUE (NA) THERAPY IN NON-CIRRHOTIC HBEAG-NEGATIVE CHRONIC HEPATITIS B (CHBE-) PATIENTS DOES NOT INCREASE THE RISK OF HEPATOCELLULAR CARCINOMA (HCC): A MULTICENTER CASE-CONTROL STUDY
    Authors: Margarita Papatheodoridi, Emilia Hadziyannis, Afroditi Orfanidou, Kalliopi Zachou, Anastasia Kourikou, Nikolaos Gatselis, Spilios Manolakopoulos, George Dalekos, Stephanos Hadziyannis, George Papatheodoridis
    You must log in to access content.
  • 0474: COMMON HEPATITIS FLARE BUT RARE HBsAg SEROCLEARANCE AFTER STOPPING NA TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHB PATIENTS
    Authors: Grace Wong, Becky Yuen, Vicki Hui, Yee-Kit Tse, Terry Cheuk-Fung Yip, Lilian Yan Liang, Henry Chan, Vincent Wong
    You must log in to access content.
  • 0477: HEP B CONSULT: A POINT-OF-CARE INTERACTIVE DECISION SUPPORT TOOL DELIVERS REAL-TIME, PERSONALIZED, GUIDELINE-BASED TEACHING AND REVEALS VARIANCE BETWEEN CLINICIANS AND GUIDELINES IN THE MANAGEMENT OF HBV INFECTION
    Authors: Zachary Schwartz, Jenny Schulz, Edward King, Kosh Agarwal, Grace Wong, Paul Kwo
    You must log in to access content.
  • 0478: RISK OF INCIDENT HEPATOCELLULAR CARCINOMA IN HEPATITIS B-INFECTED PATIENTS TREATED WITH TENOFOVIR DISOPROXIL FUMARATE VERSUS ENTECAVIR: A US ADMINISTRATIVE CLAIMS ANALYSIS
    Authors: W. Ray Kim, Laura Telep, Mei Lu, Heribert Ramroth, John Flaherty, Anuj Gaggar, Anand Chokkalingam, Stuart Gordon
    You must log in to access content.
  • 0479: REMARKABLE DIFFERENCE IN RE-TREATMENT RESPONSE IN PATIENTS WITH DIFFERENT HBsAg/ALT KINETICS DURING OFF-NUC HEPATITIS FLARE
    Authors: Wen-Juei Jeng, Yen-Chun Liu, Rong-Nan Chien, Yun-Fan Liaw
    You must log in to access content.
  • 0486: DIFFERENTIAL TENOFOVIR ALAFENAMIDE (TAF) ADOPTION IN HBV-INFECTED POPULATIONS; ASSESSMENT OF CARE IN US CLINICAL PRACTICE
    Authors: Michael Curry, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, K Rajender Reddy, Calvin Pan, Hie-Won Hann, Myron Tong, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, Nezam Afdhal
    You must log in to access content.
  • 0487:LONGER-TERM EXPERIENCE WITH TENOFOVIR ALAFENAMIDE (TAF) IN HBV-INFECTED PATIENTS; CHANGES IN EGFR, FIB4, ALT, AND DNA SUPPRESSION
    Authors: Michael Curry, Myron Tong, K Rajender Reddy, Ho Bae, Douglas Dieterich, Victor Ankoma-Sey, Calvin Pan, Hie-Won Hann, W. Ray Kim, Paul Kwo, Lynn Frazier, Kimmi Cox, Scott Milligan, Nezam Afdhal
    You must log in to access content.
  • 0488: ALT NORMALIZATION AFTER ENTECAVIR AND TENOFOVIR CORRELATED WITH REDUCTION OF DEVELOPMENT FOR HCC.
    Authors: Sehwa Kim, Sung Won Chang, Ha Seok Lee, Min-Jin Lee, Young-Sun Lee, Sang Jun Suh, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Jong eun Yeon, Soon Ho Um, Kwan Soo Byun
    You must log in to access content.
  • 0492: SHORT-TERM (4 WEEKS) SAFETY AND EFFICACY OF TENOFOVIR ALAFENAMIDE (TAF) COMPARED TO TENOFOVIR DISOPROXIL FUMARATE (TDF) AND ENTERCAVIR (ETV) IN TREATMENT-NAIVE ADULT PATIENTS WITH HBV-ACLF FROM SOUTH CHINA
    Authors: Liang Peng, Lina Wu, Yeqiong Zhang, Xiang Zhu, Xuejun Li, Limin Zhen, Wenxiong Xu
    You must log in to access content.
  • 0493: A COMPARISON OF ENTECAVIR VS. TENOFOVIR FOR RECURRENCE IN PATIENTS WITH HBV-RELATED HCC TREATED WITH CURATIVE RESECTION OR ABLATION
    Authors: Ji Hyun Lee, Beom Kyung Kim, Junyong Park, Doyoung Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
    You must log in to access content.
  • 0494: HBEAG LOSS RATE DURING NUC THERAPY WAS LOWER THAN NATURAL HISTORY IN CHB HBEAG POSITIVE PATIENTS WITH HEPATITIS FLARE
    Authors: Chien-Wei Peng, Wen-Juei Jeng, Yun-Fan Liaw
    You must log in to access content.
  • 0496: ENTECAVIR TREATMENT OF HEPATITIS B VIRUS-INFECTED PATIENTS WITH SEVERE RENAL IMPAIRMENT, INCLUDING THOSE ON HEMODIALYSIS
    Authors: Kazuharu Suzuki, Goki Suda, Masato Nakai, Takuya Sho, Koji Ogawa, Kenichi Morikawa, Naoya Sakamoto, Akihisa Nakamura, Taku Shigesawa
    You must log in to access content.
  • 0498: HBEAG LOSS INCIDENCE RATE DECLINED SHARPLY AFTER FIRST YEAR IN HBEAG POSITIVE CHRONIC HEPATITIS B PATIENTS RECEIVING NUCLEOS(T)IDE ANALOGUE THERAPY
    Authors: Chien-Wei Peng, Wen-Juei Jeng, Yun-Fan Liaw, Rong-Nan Chien
    You must log in to access content.